In Trials 1 and 2, serial spirometric evaluations were performed pre-dose and up to 12 hours after dosing in a sub-group of 562
patients (201 patients receiving STRIVERDI RESPIMAT 5 mcg, 192 patients receiving 10 mcg, and 169 patients receiving placebo)
after 12 weeks of treatment. Dosing occurred at approximately the same time of the day in the morning. The spirometric curves from
Trial 1 are displayed in Figure 2.